TECX
Tectonic Therapeutic, Inc.
NASDAQ
Listed Jun 21, 2018
Healthcare
· Biotechnology
· US
·
tectonictx.com
$26.87
After hrs
$29.00
+0.00%
Mkt Cap $504.5M
52w Low $14.39
57.7% of range
52w High $36.03
50d MA $29.53
200d MA $22.19
P/E (TTM)
-7.2x
EV/EBITDA
-1.8x
P/B
2.1x
Debt/Equity
0.0x
ROE
-29.5%
P/FCF
-6.3x
RSI (14)
—
ATR (14)
—
Beta
1.33
50d MA
$29.53
200d MA
$22.19
Avg Volume
370.6K
About
Recent Earnings
Recent Analyst Ratings
Insider Trades
Recent Filings
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
490 Arsenal Way · Watertown, MA 02472 · US
Date
Time
Est
Rptd
Surp
Base
Gap%
D1%
D2%
D3%
D4%
D5%
Guide ▲★
Feb 26, 2026
AMC
-1.11
-1.03
+7.2%
23.93
+0.8%
-2.0%
-3.9%
+2.0%
+14.5%
+16.4%
—
Nov 6, 2025
AMC
-1.05
-1.02
+2.9%
18.99
-2.0%
+1.7%
-0.6%
-0.1%
-0.7%
-7.4%
—
Aug 7, 2025
AMC
-0.98
-1.07
-9.2%
21.92
-4.2%
+1.8%
+0.9%
-0.2%
+0.8%
+11.6%
—
May 8, 2025
AMC
-1.10
-0.93
+15.5%
21.02
+0.8%
-6.0%
-1.5%
-3.9%
-5.3%
-1.6%
—
Mar 20, 2025
AMC
-1.39
-0.84
+39.6%
22.18
+4.0%
-4.6%
-3.5%
-4.3%
-14.3%
-14.7%
—
Nov 7, 2024
AMC
-0.84
-1.20
-42.9%
45.33
-3.2%
-3.0%
+1.6%
+5.3%
+3.1%
-4.6%
—
Aug 14, 2024
AMC
-1.96
-3.81
-94.4%
16.06
+1.5%
+5.2%
+6.0%
+4.9%
+3.9%
+1.2%
—
May 9, 2024
AMC
-4.32
-1.80
+58.3%
15.00
+0.0%
-1.6%
+8.0%
+3.2%
+9.6%
+11.2%
—
Mar 14, 2024
AMC
-4.04
-2.40
+40.6%
15.24
-1.6%
+2.4%
+1.6%
-0.8%
+0.8%
-1.6%
—
Sep 29, 2023
AMC
-4.22
-5.81
-37.7%
18.48
+0.0%
-0.6%
-3.2%
-4.5%
-1.3%
+2.6%
—
Jun 29, 2023
AMC
-6.49
18.29
+381.8%
10.80
+1.1%
+5.6%
+8.9%
+11.1%
+8.9%
+10.0%
—
Mar 30, 2023
AMC
-6.45
-6.80
-5.5%
11.28
+1.1%
+6.4%
+4.3%
+0.0%
-4.3%
+3.2%
—
Show 2 more
Date
Firm
Action
Grade
Target
Base
Open
Gap%
D1%
D2%
D3%
D4%
D5%
Jan 8
Truist
Maintains
Buy → Buy
—
$21.74
$21.26
-2.2%
-1.3%
-5.4%
-9.8%
-9.2%
-9.5%
May 15
Mizuho
Maintains
Outperform → Outperform
—
$19.90
$20.22
+1.6%
+4.0%
+5.5%
+17.6%
+23.4%
+13.5%
Mar 21
Wells Fargo
Maintains
Overweight → Overweight
—
$22.18
$23.06
+4.0%
-4.6%
-3.5%
-4.3%
-14.3%
-14.7%
Jan 31
Wells Fargo
Maintains
Overweight → Overweight
—
$54.84
$54.99
+0.3%
-1.3%
-7.7%
-12.5%
-14.6%
-22.3%
Nov 12
Wells Fargo
Maintains
Overweight → Overweight
—
$46.07
$47.99
+4.2%
+3.6%
+1.5%
-6.1%
-12.2%
-15.6%
Nov 11
Leerink Partners
Maintains
Outperform → Outperform
—
$43.96
$44.13
+0.4%
+4.8%
+8.6%
+6.3%
-1.6%
-8.0%
Date
Insider
Title
Type
Shares
Price
Value
Owned After
D1%
D5%
May 4, 2026
Ruddy Marcella K.
Chief Medical Officer
Sell
1,065
$30.00
$32K
67,682
-7.41%
—
8-K · 2.02
!! High
Tectonic Therapeutic, Inc. -- 8-K 2.02: Earnings Results
Tectonic Therapeutic reported Q1 2026 financial results and business updates, providing investors visibility into operational performance and strategic progress during the quarter.
May 7
8-K · 7.01
! Medium
Tectonic Therapeutic, Inc. -- 8-K 7.01: Regulation FD Disclosure
Tectonic Therapeutic (TECX) strengthened its board governance by appointing Ms. Chutter as a director and Audit Committee member, enhancing oversight capabilities.
Apr 23
8-K
Tectonic Therapeutic, Inc. -- 8-K Filing
Tectonic Therapeutic reported positive Phase 1b results for TX45 in pulmonary hypertension treatment, advancing its clinical pipeline and potentially validating its therapeutic approach for heart failure patients.
Feb 26
8-K · 7.01
! Medium
Tectonic Therapeutic, Inc. -- 8-K 7.01: Regulation FD Disclosure
Tectonic Therapeutic appointed Dr. Nader as Board Chair, signaling leadership restructuring that may influence the company's strategic direction and governance.
Feb 24
8-K
Sensei Biotherapeutics, Inc. -- 8-K Filing
Sensei Biotherapeutics appointed a new CFO with significant biotech finance experience, including prior roles at Jaguar Gene Therapy and board positions at Tectonic Therapeutic, strengthening leadership capabilities.
Feb 13
Data updated apr 27, 2026 4:23am
· Source: massive.com
